Overview and Definitional Shifts
Idiopathic Nephrotic Syndrome is the most frequent glomerular disease of childhood, characterized by heavy proteinuria ($\text{uPCR} > 2.0\text{ mg/mg}$ or $> 300\text{ mg/dL}$ / $3+$ on dipstick), hypoalbuminemia ($< 2.5\text{ g/dL}$), generalized edema, and hyperlipidemia. The International Pediatric Nephrology Association (IPNA, 2022–2023 Guidelines) updated clinical practice recommendations, establishing shorter steroid courses, biomarker-driven genetic screening, and standardized biologic protocols.
IPNA Core Clinical Classifications
flowchart TD
A["Child with First Episode Nephrotic Syndrome<br/>(uPCR > 2.0 mg/mg, Albumin < 2.5 g/dL, Edema)"] --> B["Induction Prednisolone Therapy:<br/>60 mg/m2/day (max 60 mg) for 4–6 Weeks"]
B --> C{"Urine Protein Negative/Trace at 4 Weeks?"}
C -->|Yes: Complete Remission| D["Steroid-Sensitive Nephrotic Syndrome (SSNS)"]
D --> E["Taper Prednisolone on Alternate Days for 4–6 Weeks<br/>(Total Duration: 8–12 Weeks Total)"]
C -->|No: Persistent Proteinuria| F["Steroid-Resistant Nephrotic Syndrome (SRNS)"]
F --> G["Genetic Testing (NGS Podocyte Panel)<br/>BEFORE Invasive Kidney Biopsy"]
| Clinical Phenotype | Diagnostic Definition (IPNA Criteria) |
|---|---|
| Steroid-Sensitive (SSNS) | Complete remission achieved within 4 weeks of daily prednisolone ($60\text{ mg/m}^2/\text{day}$). Remission is defined as urinary protein-to-creatinine ratio ($\text{uPCR}$) $< 0.2\text{ mg/mg}$ or negative/trace dipstick for 3 consecutive days. |
| Steroid-Resistant (SRNS) | Failure to achieve complete remission after 4 weeks of daily prednisolone at full dose. (IPNA formally deprecated the older historical 8-week definition [4 weeks daily + 4 weeks alternate-day] to avoid unnecessary high-dose steroid toxicity). |
| Frequently Relapsing (FRNS) | $\ge 2$ relapses within 6 months of initial response, OR $\ge 4$ relapses within any 12-month period. |
| Steroid-Dependent (SDNS) | $\ge 2$ consecutive relapses occurring during steroid dose tapering or within 14 days of steroid cessation. |
Shortened Initial Steroid Regimen
Clinical Evidence: The PREDNOS and Pedi-RCR Trials
- Historically, international protocols prescribed 12 to 24 weeks of initial steroids to reduce relapses.
- Landmark multicenter randomized controlled trials (PREDNOS trial, Lancet 2019; Pedi-RCR trial) proved that extending steroid therapy beyond 8 to 12 weeks does not reduce the rate of subsequent relapses, the proportion of frequent relapsers, or time to first relapse.
- Current IPNA Recommendation:
- Daily Prednisolone: $60\text{ mg/m}^2/\text{day}$ (max $60\text{ mg}$) for 4 to 6 weeks.
- Followed by Alternate-Day Prednisolone: $40\text{ mg/m}^2$ on alternate days for 4 to 6 weeks.
- Total Course: 8 to 12 weeks. This minimizes growth failure, bone demineralization, Cushingoid habitus, and behavioral disturbances.
Steroid-Sparing Strategies in FRNS / SDNS
For children who develop steroid dependency or frequent relapses, steroid-sparing maintenance agents are indicated to maintain sustained remission while sparing linear growth:
| Agent | Mechanism | Dosing & Regimen | Clinical Monitoring & Caveats |
|---|---|---|---|
| Levamisole | Immunomodulator; stimulates Th1 cytokines and glucocorticoid receptor expression | $2.5\text{ mg/kg}$ on alternate days for 12 to 24 months | First-line steroid-sparing agent for mild SDNS/FRNS. Excellent safety profile. Monitor CBC every 8–12 weeks to detect rare reversible neutropenia / agranulocytosis or ANCA vasculitis. |
| Mycophenolate Mofetil (MMF) | Inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo purine synthesis in lymphocytes | $1,200\text{ mg/m}^2/\text{day}$ orally in two divided doses ($30–40\text{ mg/kg/day}$) | Highly effective in sustaining remission and tapering steroids. Measure mycophenolic acid (MPA) 12-hour AUC (target: $> 30–60\ \mu\text{g}\cdot\text{h/mL}$); monitor for diarrhea and leukopenia. |
| Calcineurin Inhibitors (CNIs) (Tacrolimus, Cyclosporine) | Inhibits calcineurin phosphatase, preventing IL-2 transcription in T cells; stabilizes podocyte synaptopodin | Tacrolimus: $0.1–0.15\text{ mg/kg/day}$ (12-hour trough target: $4–8\text{ ng/mL}$). Cyclosporine: $4–5\text{ mg/kg/day}$ (trough $80–120\text{ ng/mL}$). | Powerful antiproteinuric effect; first-line therapy for SRNS. Chronic risk of nephrotoxicity (tubular atrophy, interstitial fibrosis); protocol kidney biopsy recommended after 2–3 years of continuous therapy. |
Targeted Biologic Therapy: Rituximab and Anti-CD20 Monoclonal Antibodies
flowchart TD
A["Indications for Rituximab:<br/>1. Difficult / Complicated SDNS failing oral steroid-sparing agents (MMF / Levamisole)<br/>2. Calcineurin Inhibitor Dependence or Nephrotoxicity<br/>3. Severe steroid toxicity (growth failure, cataracts, severe osteopenia)"] --> B["Pre-Treatment Screening:<br/>• Total Serum IgG & IgM (Pre-existing hypogammaglobulinemia)<br/>• Hepatitis B & Latent Tuberculosis screening<br/>• Baseline CD19+ B-cell quantification"]
B --> C["Administration Protocol:<br/>Single Dose: 375 mg/m2 IV Infusion<br/>(Premedicate with Paracetamol + Antihistamine + Methylprednisolone)"]
C --> D["Post-Infusion Monitoring:<br/>• Flow cytometry at 48–72h: Confirm complete B-cell depletion (CD19 < 1%)<br/>• Serial CD19 tracking every 1–2 months"]
D --> E{"Clinical Course"}
E -->|"Sustained Remission"| F["Maintain off all oral immunosuppression / steroids"]
E -->|"B-cell Recovery (> 1%) + Clinical Relapse"| G["Consider repeat single-dose Rituximab"]
1. Dosing Protocols
- Single-Dose Protocol: An initial single infusion of $375\text{ mg/m}^2$ achieves complete peripheral CD19+ B-cell depletion ($<1\%$ of total lymphocytes) in $>95\%$ of pediatric patients, providing equivalent 1-year remission rates compared to older 4-dose weekly regimens while reducing cost and adverse events.
- Efficacy: Induces complete, medication-free remission in $> 70–80\%$ of children with complicated SDNS, halts steroid-induced growth deceleration, and enables withdrawal of CNIs.
- Repeat Dosing Strategy: Redosing is guided by clinical relapse rather than preemptively at the time of B-cell reconstitution.
2. Adverse Events and Safety Surveillance
- Infusion Reactions: Fever, chills, bronchospasm, urticaria; managed via premedication.
- Secondary Hypogammaglobulinemia: Occurs in $10–20\%$ of children, particularly those aged $<5$ years. Baseline serum IgG must be quantified; if profound post-infusion IgG drop occurs ($<300–400\text{ mg/dL}$), replacement Intravenous Immunoglobulin (IVIG) is required to prevent life-threatening encapsulated bacterial infections.
- Second-Generation Agent (Ofatumumab): Fully human anti-CD20 mAb binding a distinct epitope; indicated for patients with refractory disease who develop neutralizing anti-rituximab antibodies.
Genetic Testing in Steroid-Resistant Nephrotic Syndrome (SRNS)
"Genetics First" Diagnostic Algorithm
IPNA guidelines mandate comprehensive Next-Generation Sequencing (NGS) podocyte gene panels (NPHS1 [Nephrin], NPHS2 [Podocin], WT1, LAMB2, PLCE1, ACTN4, INF2) prior to performing a percutaneous kidney biopsy, especially in:
- Congenital nephrotic syndrome (onset $< 3\text{ months}$).
- Infantile nephrotic syndrome (onset $3–12\text{ months}$).
- Children with family history of consanguinity or nephrotic syndrome.
- Primary steroid resistance with syndromic extra-renal features (Frasier, Denys-Drash, Pierson, Schimke syndromes).
Clinical Consequences of Identifying a Genetic Podocytopathy
- Immediate Cessation of Immunosuppression: Monogenic podocyte structural mutations do not respond to steroids, CNIs, or rituximab. Withdrawing toxic immunosuppression prevents futile drug exposure.
- Post-Transplant Recurrence Prediction: Genetic SRNS carries an extremely low risk of disease recurrence in a kidney allograft ($< 5\%$), whereas non-genetic immunological SRNS carries a high recurrence risk of $30–50\%$.